ABSTRAK Latar Belakang: Perlunya stratifikasi risiko dan evaluasi terapi berkala pada
sindrom koroner akut (SKA) terkait mortalitas dan morbiditas di kemudian hari.
Petanda biokimia ST2 praktis dan lebih murah, serta tidak dipengaruhi oleh usia,
jenis kelamin dan fungsi ginjal. Kadarnya dapat berbeda antar ras, namun belum
ada data yang menyajikan profil kadar ST2 awal dan penurunan pasca terapi
definitif di Indonesia.
Metode: Studi deskriptif longitudinal pada 40 subjek yang diperiksan kadar ST2
secara ELISA saat awal dan setelah terapi definitif.
Hasil: Didapatkan proporsi kadar ST2 awal <35 ng/mL lebih dominan ( 52,5% vs.
47,5%). Kadar ST2 awal tertinggi didapatkan pada IMA-NST, yaitu 46,79 ng/mL
(kuartil-1 3,67 ng/mL, dan kuartil-3 102,41 ng/mL) yang memiliki awitan terlama
(48 jam). Hipertensi memiliki proporsi tertinggi (91,7%) dan usia berbanding lurus
dengan kadar ST2. Proporsi kadar ST2 yang tidak mengalami penurunan sebesar
30%, terutama APTS (41,7%) dengan usia rerata 3 tahun lebih tua (58 tahun vs. 55
tahun).
Simpulan: Didapatkan kadar ST2 <35 ng/mL pada sebagian besar subjek, tertinggi
pada IMA-NST. Lama awitan, hipertensi dan usia diduga berhubungan dengan
kadar ST2 awal tinggi. Kadar ST2 pasca terapi menurun pada sebagian besar subjek.
ABSTRACT Background: Acute coronary syndrome been a burden for causing high mortality
and morbidity, therefore risk stratification and therapy evaluation are needed. A
new biomarker ST2 is practice and less expensive for daily usage and it also doesn?t
influenced by age, gender, and kidney function. The ST2 value are different in due
to race among countires. There is no data available regarding ST2 baseline and after
definitive treatment profile in Indonesia.
Method: It is a longitudinal descriptive study that conducted prospectively on 40
subjects. The value of ST2 was examined using ELISA methods at baseline and
after definite treatment.
Result: The proporsion of baseline ST2 <35 ng/mL are dominan (52,5% vs.
47,5%). The highest of ST2 baseline value are found in NSTEMI-ACS it?s 46,79
ng/mL (kuartil-1 3,67 ng/mL, dan kuartil-3 102,41 ng/mL) and it also had the
longest onset of chest pain (48 hours). Hypertension had the highest proporsion
(91,7%) and age were proportional to the ST2 value. The proportion of the ST2
value that didn?t decreased after therapy were lesser than the decrease (30% vs.
70%), especially UAP (41,7%) that had 3 years older ages (58 years old vs. 55 years
old).
Conclusion: Proportion of baseline of ST2 value <35 ng/mL groups were higher
than ST2 level ≥35 ng/mL (52,5% vs. 47,5%), and the highest baseline ST2 level
were found in NSTEMI-ACS. Onset of angina, hypertension and age were found
to be dominant in patient with early ST2 level ≥35 ng/mL. The ST2 value were decreasing in most of the subject after treatment. ;Background: Acute coronary syndrome been a burden for causing high mortality
and morbidity, therefore risk stratification and therapy evaluation are needed. A
new biomarker ST2 is practice and less expensive for daily usage and it also doesn?t
influenced by age, gender, and kidney function. The ST2 value are different in due
to race among countires. There is no data available regarding ST2 baseline and after
definitive treatment profile in Indonesia.
Method: It is a longitudinal descriptive study that conducted prospectively on 40
subjects. The value of ST2 was examined using ELISA methods at baseline and
after definite treatment.
Result: The proporsion of baseline ST2 <35 ng/mL are dominan (52,5% vs.
47,5%). The highest of ST2 baseline value are found in NSTEMI-ACS it?s 46,79
ng/mL (kuartil-1 3,67 ng/mL, dan kuartil-3 102,41 ng/mL) and it also had the
longest onset of chest pain (48 hours). Hypertension had the highest proporsion
(91,7%) and age were proportional to the ST2 value. The proportion of the ST2
value that didn?t decreased after therapy were lesser than the decrease (30% vs.
70%), especially UAP (41,7%) that had 3 years older ages (58 years old vs. 55 years
old).
Conclusion: Proportion of baseline of ST2 value <35 ng/mL groups were higher
than ST2 level ≥35 ng/mL (52,5% vs. 47,5%), and the highest baseline ST2 level
were found in NSTEMI-ACS. Onset of angina, hypertension and age were found
to be dominant in patient with early ST2 level ≥35 ng/mL. The ST2 value were decreasing in most of the subject after treatment. ;Background: Acute coronary syndrome been a burden for causing high mortality
and morbidity, therefore risk stratification and therapy evaluation are needed. A
new biomarker ST2 is practice and less expensive for daily usage and it also doesn?t
influenced by age, gender, and kidney function. The ST2 value are different in due
to race among countires. There is no data available regarding ST2 baseline and after
definitive treatment profile in Indonesia.
Method: It is a longitudinal descriptive study that conducted prospectively on 40
subjects. The value of ST2 was examined using ELISA methods at baseline and
after definite treatment.
Result: The proporsion of baseline ST2 <35 ng/mL are dominan (52,5% vs.
47,5%). The highest of ST2 baseline value are found in NSTEMI-ACS it?s 46,79
ng/mL (kuartil-1 3,67 ng/mL, dan kuartil-3 102,41 ng/mL) and it also had the
longest onset of chest pain (48 hours). Hypertension had the highest proporsion
(91,7%) and age were proportional to the ST2 value. The proportion of the ST2
value that didn?t decreased after therapy were lesser than the decrease (30% vs.
70%), especially UAP (41,7%) that had 3 years older ages (58 years old vs. 55 years
old).
Conclusion: Proportion of baseline of ST2 value <35 ng/mL groups were higher
than ST2 level ≥35 ng/mL (52,5% vs. 47,5%), and the highest baseline ST2 level
were found in NSTEMI-ACS. Onset of angina, hypertension and age were found
to be dominant in patient with early ST2 level ≥35 ng/mL. The ST2 value were decreasing in most of the subject after treatment. ;Background: Acute coronary syndrome been a burden for causing high mortality
and morbidity, therefore risk stratification and therapy evaluation are needed. A
new biomarker ST2 is practice and less expensive for daily usage and it also doesn?t
influenced by age, gender, and kidney function. The ST2 value are different in due
to race among countires. There is no data available regarding ST2 baseline and after
definitive treatment profile in Indonesia.
Method: It is a longitudinal descriptive study that conducted prospectively on 40
subjects. The value of ST2 was examined using ELISA methods at baseline and
after definite treatment.
Result: The proporsion of baseline ST2 <35 ng/mL are dominan (52,5% vs.
47,5%). The highest of ST2 baseline value are found in NSTEMI-ACS it?s 46,79
ng/mL (kuartil-1 3,67 ng/mL, dan kuartil-3 102,41 ng/mL) and it also had the
longest onset of chest pain (48 hours). Hypertension had the highest proporsion
(91,7%) and age were proportional to the ST2 value. The proportion of the ST2
value that didn?t decreased after therapy were lesser than the decrease (30% vs.
70%), especially UAP (41,7%) that had 3 years older ages (58 years old vs. 55 years
old).
Conclusion: Proportion of baseline of ST2 value <35 ng/mL groups were higher
than ST2 level ≥35 ng/mL (52,5% vs. 47,5%), and the highest baseline ST2 level
were found in NSTEMI-ACS. Onset of angina, hypertension and age were found
to be dominant in patient with early ST2 level ≥35 ng/mL. The ST2 value were decreasing in most of the subject after treatment.
SP-Indhira Alimin.pdf :: Unduh